Key Insights• The Italy biosurgery market represents one of the largest and most established national markets for surgical biomaterials in Europe. The market encompasses a broad range of biologically derived and bio-compatible materials including hemostatic agents, surgical sealants and adhesives, bone-graft substitutes, adhesion barriers, soft-tissue attachments, and staple-line reinforcement products that assist in surgical procedures by controlling bleeding, sealing tissues, promoting regeneration, and preventing postoperative complications.• The Italy biosurgery market is distinguished by its universal healthcare system (Servizio Sanitario Nazionale), advanced clinical infrastructure, and significant surgical volumes. According to ISTAT data, healthcare expenditure in Italy reached €190.1 billion in 2025, representing 8.4% of GDP. The public sector financed €140.8 billion (74.1%) of total spending, while €42.4 billion (22.3%) was directly borne by households. The market is shaped by a complex interplay of demographic trends, technological innovation, regulatory frameworks, and evolving healthcare delivery models.• Italy's healthcare expenditure reached €190.1 billion in 2025, representing 8.4% of GDP, with the public sector accounting for 74.1% of total spending. This substantial healthcare investment provides the financial foundation for sustained surgical activity and biosurgical product utilization.

Bone-Graft Substitutes represent the largest product category within the Italian biosurgery market, driven by the high volume of orthopedic procedures. Hip and knee prostheses are among the most frequently performed surgeries in Italy.• Surgical Sealants and Adhesives represent the fastest-growing product category, driven by increasing adoption of minimally invasive surgical techniques across Italian hospitals and private clinics. Italy's aging population represents a significant long-term demand driver. As of January 1, 2025, over 14.5 million people (24.7% of the population) were aged 65 years or older, with over 4.59 million aged 80 and above. The average age reached 46.8 years, the highest in the EU. The regulatory environment, centered on the European Medical Device Regulation (MDR) and the Italian Ministry of Health's Direzione Generale dei Dispositivi Medici (DGDMF), plays a decisive role in shaping market dynamics.Market Outlook• According to the research report, "Italy Biosurgery Market Overview, 2031," published by Actual Market Research, the Italy Biosurgery Market is expected to reach a market size of more than USD 342 Million by 2031.The Italian biosurgery market is expected to maintain steady growth through 2031, supported by favorable demographic trends, ongoing technological innovation, and expanding surgical volumes across both public hospitals and private clinics.

The market's growth trajectory is intrinsically linked to the broader Italian healthcare landscape, including healthcare expenditure, technological adoption, and demographic shifts.• Italy's healthcare expenditure reached €190.1 billion in 2025， representing 8.4% of GDP. Public healthcare spending as a percentage of GDP stood at 6.2% in 2025, placing Italy twenty-fifth out of 38 OECD countries. Healthcare spending per capita was approximately $5,164，below the OECD average of $5,967.• The aging Italian population represents the most significant long-term demand driver. As of January 1, 2025, 24.7% of the population (over 14.5 million people) was aged 65 years or older. The number of centenarians reached a new high of over 23,500 people. Life expectancy in Italy reached 83.7 years in 2025.Technological innovation in biomaterials and surgical delivery systems is expanding the addressable market.

The Italian National Institute of Health (ISS) supports market surveillance and post-marketing surveillance of medical devices, particularly for high-risk Class III devices for cardiovascular and orthopedic applications.• Rising surgical procedures are a key driver propelling market expansion. The five most frequent surgical operations cataract surgery, hip and knee prostheses, cholecystectomy, inguinal hernia, and cesarean section involve approximately 1.2 million patients annually and generate a total cost for the SSN of approximately €3 billion.Market DynamicsDriver: High Surgical Volumes and Aging PopulationItaly performs over 1.2 million high-frequency surgical procedures annually across public hospitals, private clinics, and accredited facilities. Cataract surgery is the most frequently performed procedure, followed by hip and knee prostheses, cholecystectomy, inguinal hernia repair, and cesarean sections. The aging population with 24.7% aged 65 and older and 4.59 million aged 80 and above continues to drive demand for musculoskeletal and ophthalmic interventions. The impact of the over-50 population on the SSN in 2025 was equivalent to 83.8 million people, nearly three times their actual number, and is projected to reach 94.9 million by 2040. Healthcare expenditure of €190.1 billion (8.4% of GDP) provides the financial infrastructure to support expanding surgical volumes.

The breadth and depth of surgical activity in Italy ensure that biosurgical products particularly hemostatic agents and sealants are utilized in virtually every operating room.Challenge: Healthcare Spending Constraints and Waiting ListsDespite significant healthcare investment, Italy faces persistent challenges that limit the full potential of the biosurgery market. Public healthcare spending in Italy stands at 6.2% of GDP, placing the country twenty-fifth out of 38 OECD countries. Healthcare spending per capita of approximately $5,164 is below the OECD average of $5,967. Total health spending in Italy declined from 8.7% of GDP in 2019 to 8.4% in 2025, diverging from the international trend. Waiting lists remain a structural challenge, with times for procedures such as cataract and hip or knee prostheses sometimes exceeding one year. Additionally, 5.8 million citizens in 2024 renounced medical visits or examinations despite needing them.

These financial and operational constraints create pricing pressure on biosurgical products and may limit adoption of premium-priced advanced biologics.Trend: Accelerating Adoption of Minimally Invasive and Robotic Surgical TechniquesThe Italian biosurgery market is experiencing a significant trend toward minimally invasive and robotic surgical techniques. The adoption of robotic surgical systems is expanding across Italian hospitals, with technologies enabling more complex procedures to be performed with greater precision and reduced patient trauma. The ISS has established a National Center for Innovative Technologies in Public Health, focusing on personalized prostheses and therapeutic devices based on advanced materials and 3D printing. This shift toward advanced surgical platforms creates new opportunities for biosurgical products specifically designed for minimally invasive and robotic applications. Surgical sealants and adhesives that can be delivered through small incisions, hemostatic agents optimized for sprayable application, and staple-line reinforcement products compatible with robotic staplers are increasingly in demand.Policies• The European Medical Device Regulation (MDR) (EU) 2017/745 serves as the core regulatory framework for biosurgical products in Italy. Manufacturers must comply with MDR requirements for clinical evaluation, post-market surveillance, and product labeling.• The Italian Ministry of Health - Direzione Generale dei Dispositivi Medici e del servizio Farmaceutico (DGDMF) serves as the competent authority for medical devices in Italy, overseeing implementation of the MDR and managing the national medical device database.• The Italian Classification of Medical Devices (CID) entered into force on January 1, 2026, fully replacing the National Classification of Medical Devices (CND) in use since 2007.• Legislative Decree 137/2022 governs the submission of device investigations in Italy, with the Ministry of Health serving as the competent authority and requiring ethics opinion from Territorial or National Ethics Committees.• The Istituto Superiore di Sanità (ISS) serves as Italy's National Institute of Health and operates a Notified Body (ON ISS) carrying out CE certification activities for medical devices.

The ISS also supports market surveillance and post-marketing surveillance of medical devices.• Medical device registration in the Italian Ministry of Health database is mandatory through the NSIS System (Nuovo Sistema Informativo Sanitario), with manufacturers requiring SPID or CNS credentials for access.Segment AnalysisItaly Biosurgery Market By Product• Bone-Graft Substitutes represent the largest product category within the Italian biosurgery market, driven by the high volume of orthopedic procedures. Hip and knee prostheses are among the most frequently performed surgeries in Italy, with approximately 125,000 hip prostheses performed annually. These products include demineralized bone matrix (DBM), synthetic bone grafts, and biologic grafts incorporating growth factors. The aging Italian population with 24.7% aged 65 and older continues to drive demand for musculoskeletal interventions requiring bone-graft substitutes.• Hemostatic Agents constitute a major market segment, reflecting their essential role across all surgical disciplines. These products including topical hemostats, flowable matrices, fibrin sealants, and thrombin-based agents are utilized in virtually every surgical procedure to control intraoperative bleeding. The increasing volume of surgeries and growing demand for effective hemostatic solutions contribute to the strength of this segment.• Surgical Sealants and Adhesives represent the fastest-growing product category in the Italian biosurgery market, driven by increasing adoption of minimally invasive and robotic surgical techniques.

These products including fibrin sealants, synthetic polymer-based sealants, and protein-based adhesives are used to seal tissue surfaces, prevent fluid and air leaks, and reinforce surgical anastomoses. The ISS's focus on innovative technologies, including personalized prostheses and advanced materials, supports the expansion of this segment.• Adhesion Barriers represent a clinically important product category used to prevent postoperative adhesion formation in abdominal, pelvic, and gynecological surgeries. The category continues to benefit from ongoing product innovation and clinical evidence supporting adhesion prevention, particularly as the volume of gynecological and abdominal procedures remains substantial.• Soft-Tissue Attachments encompass products used to reinforce, repair, or secure soft tissues, including surgical meshes, biologic scaffolds, and tissue grafts. These products are utilized in hernia repair, pelvic floor reconstruction, and various other soft-tissue procedures supported by high procedure volumes in Italian hospitals and private clinics.• Staple-Line Reinforcement products are utilized in gastrointestinal, bariatric, and thoracic procedures to strengthen tissue interfaces along surgical staple lines, reducing the risk of bleeding and leakage. The increasing volume of thoracic and gastrointestinal procedures supports steady demand for these products.Italy Biosurgery Market By Application• Orthopedic Surgery is the largest application area for biosurgical products in Italy, driven by the high volume of hip and knee prostheses. Approximately 125,000 hip prostheses are performed annually.

The aging Italian population with over 14.5 million aged 65 and older continues to drive demand for musculoskeletal interventions. The ISS provides specialized support for high-risk Class III medical devices for orthopedic applications.• General Surgery encompasses a broad range of abdominal, gastrointestinal, and soft-tissue procedures, including cholecystectomy, inguinal hernia repair, bariatric surgery, and colorectal surgery. Biosurgical products utilized include hemostatic agents, surgical sealants, staple-line reinforcement products, and adhesion barriers. Cholecystectomy and inguinal hernia repair are among the five most frequent surgical operations in Italy.• Cardiovascular Surgery represents the fastest-growing application area in the Italian biosurgery market, driven by the high prevalence of cardiovascular disease in the aging population. Vascular sealants, hemostatic agents, and soft-tissue attachments are increasingly utilized in cardiac and vascular procedures. The ISS provides specialized support for high-risk Class III medical devices for cardiovascular applications.• Neurological Surgery utilizes biosurgical products particularly hemostatic agents and dural sealants to manage bleeding and prevent cerebrospinal fluid leaks in cranial and spinal procedures.

The aging population and increasing incidence of neurological conditions drive demand in this specialty.• Reconstructive Surgery involves the use of biosurgical products to restore, repair, or reconstruct damaged or surgically altered tissues, including soft-tissue repair, tissue reinforcement, and wound reconstruction following injury, disease, or surgery.• Gynecological Surgery includes biosurgical applications in procedures involving the female reproductive system, with products used for hemostasis, tissue sealing, adhesion prevention, tissue repair, and reinforcement. Cesarean section is among the five most frequent surgical operations in Italy.• Urological Surgery covers biosurgical applications in procedures involving the urinary tract and male reproductive system, with products used for bleeding control, tissue sealing, reinforcement, repair, and prevention of postoperative complications.• Thoracic and Other Surgeries represent a growing application area, driven by increasing adoption of video-assisted thoracoscopic surgery (VATS) and the rising burden of lung cancer and other thoracic conditions.Italy Biosurgery Market By Source/Origin• Biologic products represent the largest source category in the Italian biosurgery market, driven by their superior biocompatibility and natural healing properties. These products include demineralized bone matrix, fibrin sealants, collagen hemostats, allografts, and xenografts. The MDR's rigorous requirements for biological materials ensure high safety standards and support market confidence.• Synthetic and Semi-Synthetic products represent the fastest-growing source category in the Italian market, driven by cost-effectiveness, consistent quality, lower immunogenicity risks, and longer shelf life. These products include synthetic bone substitutes, PEG-based sealants, synthetic meshes, and polysaccharide hemostats. The Italian healthcare system's emphasis on cost-effectiveness favors synthetic alternatives for certain applications.Italy Biosurgery Market By End-User• Hospitals remain the largest end-user segment for biosurgical products in Italy, accounting for the majority of revenue.

In 2024, SSN spending on hospital admissions reached €28.6 billion, an increase of 7.9% compared to €26.5 billion in 2020. The concentration of complex surgical procedures and availability of specialized surgical teams make hospitals the primary setting for biosurgical product utilization.• Ambulatory Surgical Centers (ASCs) represent the fastest-growing end-user segment in the Italian biosurgery market, driven by the broader healthcare industry shift toward outpatient and same-day discharge models. The expansion of outpatient surgical capacity, supported by the network of private clinics and accredited facilities, supports the adoption of biosurgical products in these settings.• Clinics represent a growing end-user segment, with specialty clinics performing eligible surgical or minimally invasive procedures utilizing biosurgical products for tissue repair, bleeding control, and sealing.Italy Biosurgery Procedure Economics• The Italian biosurgery market operates within a universal healthcare system led by the Servizio Sanitario Nazionale (SSN), with regional health authorities playing a major role in reimbursement and procurement. Healthcare expenditure reached €190.1 billion in 2025, equivalent to 8.4% of GDP, while public healthcare spending represented 6.2% of GDP. Medical devices are reimbursed through regional formularies and tenders, creating substantial regional variation. Manufacturers must demonstrate clinical efficacy, cost-effectiveness, and economic value to secure favorable positions, while the Ministry of Health’s medical device database provides the national registry for products placed on the Italian market.• Procurement is conducted through regional health authority tenders, hospital-level agreements, and surgeon preferences, with increasing regional consolidation intensifying pricing competition for commoditized biosurgical products.

Manufacturers must therefore navigate procurement requirements across Italy’s 20 regions, where healthcare access and purchasing practices can differ considerably. Italy has an extensive network of public hospitals, private clinics, and accredited facilities, while SSN hospital-admission spending reached €28.6 billion in 2024, 7.9% higher than in 2020. Established distribution networks and skilled manufacturing capabilities also support Italy’s role as a strategic European production and commercial market.• Italy benefits from a substantial surgical workforce, with 26.6% of specialist physicians working in surgical fields and approximately 217,000 active specialist physicians in 2024. However, workforce aging remains an important challenge. Innovation is supported by the Istituto Superiore di Sanità (ISS), particularly through initiatives involving personalized prostheses, advanced materials, 3D printing, and health technology assessment. The regulatory framework follows the European MDR under Ministry of Health oversight, while the Italian Classification of Medical Devices entered into force in January 2026.

ON ISS also provides notified-body certification activities for medical devices.• Technology adoption is increasing across robotic-assisted surgery, minimally invasive procedures, cardiovascular applications, orthopedic technologies, and advanced biomaterials, creating opportunities for specialized biosurgical products. Italy’s long-term market prospects are strengthened by its aging population, with 24.7% aged 65 or older and projections indicating that approximately one-third of the population could exceed 65 by 2050. Despite persistent regional disparities and procurement complexity, healthcare investment and technological development provide a favorable foundation for growth. The Italy biosurgery market is projected to exceed USD 342 million by 2031, offering significant opportunities for manufacturers able to navigate regional procurement, regulation, and competition.Considered in this report• Historic Year: 2020• Base year: 2025• Estimated year: 2026• Forecast year: 2031Aspects covered in this report• Biosurgery Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Product• Bone-Graft Substitutes• Hemostatic Agents• Surgical Sealants & Adhesives• Adhesion Barriers• Soft-Tissue Attachments• Staple-Line ReinforcementBy Application:• Orthopedic Surgery • General Surgery • Neurological Surgery • Cardiovascular Surgery • Reconstructive Surgery • Gynecological Surgery • Urological Surgery • Other surgeries (Thoracic surgeries & more)By Source/Origin• Biologic• Synthetic / Semi-syntheticBy End-user:• Hospitals • Ambulatory Surgical Centers • Clinics • Others.